Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort

被引：0
|
作者：
Wu, L. [1 ]
Zhu, J. [2 ]
Yin, R. [3 ,4 ]
Wu, X. [5 ]
Lou, G. [6 ]
Wang, J. [7 ]
Gao, Y. [8 ]
Kong, B. [9 ]
Lu, X. [10 ]
Zhou, Q. [11 ]
Wang, Y. [12 ]
Chen, Y. [13 ]
Lu, W. [14 ]
Li, W. [15 ]
Cheng, Y. [16 ]
Liu, J. [17 ,18 ]
Ma, X. [19 ]
Zhang, J. [19 ]
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Gynecol Oncol, Beijing, Peoples R China
[2] Zhejiang Canc Hosp, Dept Gynecol Oncol, Hangzhou, Zhejiang, Peoples R China
[3] Sichuan Univ, Dept Gynecol & Obstet, Chengdu, Sichuan, Peoples R China
[4] Sichuan Univ, West China Univ Hosp 2, Minist Educ, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Chengdu, Sichuan, Peoples R China
[5] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol Oncol, Shanghai, Peoples R China
[6] Harbin Med Univ, Canc Hosp, Dept Gynecol & Oncol, Harbin, Heilongjiang, Peoples R China
[7] Hunan Canc Hosp, Dept Gynecol Oncol, Changsha, Hunan, Peoples R China
[8] Beijing Canc Hosp, Dept Gynecol Oncol, Beijing, Peoples R China
[9] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan, Shandong, Peoples R China
[10] Fudan Univ, Dept Gynecol Oncol, Obstet & Gynecol Hosp, Shanghai, Peoples R China
[11] Chongqing Canc Hosp, Chongqing Off Canc Control & Res, Chongqing, Peoples R China
[12] Xian Jiatong Univ, Sch Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
[13] Soochow Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Suzhou, Peoples R China
[14] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China
[15] First Hosp Jilin Univ, Ctr Oncol, Changchun, Jilin, Peoples R China
[16] Jilin Canc Hosp, Div Thorac Oncol, Changchun, Jilin, Peoples R China
[17] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China
[18] Sun Yat Sen Univ, Dept Gynecol Oncol, Ctr Canc, Guangzhou, Guangdong, Peoples R China
[19] AstraZeneca, Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
230P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort.
    Wu, Lingying
    Zhu, Jianqing
    Yin, Rutie
    Wu, Xiaohua
    Lou, Ge
    Wang, Jing
    Gao, Yunong
    Kong, Beihua
    Lu, Xin
    Zhou, Qi
    Wang, Yueling
    Chen, Youguo
    Lu, Weiguo
    Li, Wei
    Cheng, Ying
    Liu, Jihong
    Ma, Xin
    Zhang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort
    Wu, Lingying
    Zhu, Jianqing
    Yin, Rutie
    Wu, Xiaohua
    Lou, Ge
    Wang, Jing
    Gao, Yunong
    Kong, Beihua
    Lu, Xin
    Zhou, Qi
    Wang, Yueling
    Chen, Youguo
    Lu, Weiguo
    Li, Wei
    Cheng, Ying
    Liu, Jihong
    Ma, Xin
    Zhang, Jing
    GYNECOLOGIC ONCOLOGY, 2021, 160 (01) : 175 - 181
  • [3] Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.
    Friedlander, Michael
    Moore, Kathleen N.
    Colombo, Nicoletta
    Scambia, Giovanni
    Kim, Byoung-Gie
    Oaknin, Ana
    Lisyanskaya, Alla Sergeevna
    Floquet, Anne
    Leary, Alexandra
    Sonke, Gabe S.
    Gourley, Charlie
    Banerjee, Susana N.
    Oza, Amit M.
    Gonzalez-Martin, Antonio
    Aghajanian, Carol
    Bradley, William Hampton
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    Disilvestro, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Moore, K. N.
    Colombo, N.
    Scambia, G.
    Kim, B-G.
    Oaknin, A.
    Friedlander, M.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A. M.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Lowe, E. S.
    Bloomfield, R.
    DiSilvestro, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 727 - 727
  • [5] Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Friedlander, M.
    Moore, K.
    Colombo, N.
    Scambia, G.
    Kim, B-G.
    Oaknin, A.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A. M.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Lowe, E. S.
    Bloomfield, R.
    Disilvestro, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.
    Colombo, Nicoletta
    Moore, Kathleen N.
    Scambia, Giovanni
    Oaknin, Ana
    Friedlander, Michael
    Lisyanskaya, Alla Sergeevna
    Floquet, Anne
    Leary, Alexandra
    Sonke, Gabe S.
    Gourley, Charlie
    Banerjee, Susana N.
    Oza, Amit M.
    Gonzalez-Martin, Antonio
    Aghajanian, Carol
    Bradley, William Hampton
    Kim, Jae-Weon
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    Disilvestro, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
    Friedlander, M. L.
    Moore, K.
    Colombo, N.
    Scambia, G.
    Kim, B-G.
    Oaknin, A.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Holmes, E.
    Lowe, E. S.
    Disilvestro, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1334 - S1334
  • [8] Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
    Banerjee, S.
    Moore, K. N.
    Colombo, N.
    Scambia, G.
    Kim, B-G.
    Oaknin, A.
    Friedlander, M.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Oza, A.
    Gonzalez Martin, A.
    Aghajanian, C.
    Bradley, W.
    Holmes, E.
    Lowe, E. S.
    DiSilvestro, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S613 - S613
  • [9] Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
    Colombo, Nicoletta
    Moore, Kathleen
    Scambia, Giovanni
    Oaknin, Ana
    Friedlander, Michael
    Lisyanskaya, Alla
    Floquet, Anne
    Leary, Alexandra
    Sonke, Gabe S.
    Gourley, Charlie
    Banerjee, Susana
    Oza, Amit
    Gonzalez-Martin, Antonio
    Aghajanian, Carol
    Bradley, William H.
    Kim, Jae-Weon
    Mathews, Cara
    Liu, Joyce
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    DiSilvestro, Paul
    GYNECOLOGIC ONCOLOGY, 2021, 163 (01) : 41 - 49
  • [10] Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.
    Mathews, Cara Amanda
    Moore, Kathleen N.
    Colombo, Nicoletta
    Scambia, Giovanni
    Kim, Byoung-Gie
    Oaknin, Ana
    Friedlander, Michael
    Lisyanskaya, Alla Sergeevna
    Floquet, Anne
    Leary, Alexandra
    Sonke, Gabe S.
    Gourley, Charlie
    Banerjee, Susana N.
    Oza, Amit M.
    Gonzalez-Martin, Antonio
    Aghajanian, Carol
    Bradley, William Hampton
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    Disilvestro, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345